Overview

Tenoten® in the Treatment of Somatoform, Stress-related and Other Neurotic Disorders

Status:
Completed
Trial end date:
2018-09-22
Target enrollment:
Participant gender:
Summary
The purposes of this study are: - To further examine the efficacy and safety of Tenoten® in the treatment of anxiety in patients with somatoform, stress-related and other neurotic disorders. - To compare the efficacy of two dosing regimens of Tenoten® (4 tablets daily vs.8 tablets daily, both for 12 weeks) in the treatment of anxiety in patients with somatoform, stress-related and other neurotic disorders.
Phase:
Phase 4
Details
Lead Sponsor:
Materia Medica Holding